2 Glycogenosis
UMLS: C0017921
Basic Information
Severity Level:
Severe
Based on 4 similar ADEs (max similarity: 0.515), includes 4 severe case(s)
Definition:
An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4)
UMLS ID:
C0017921
MeSH ID:
Synonyms:
2 Glycogenosis
Alpha Glucosidase Deficiency
Alpha-Glucosidase Deficiency
Amd - Acid Maltase Deficiency
Acid Maltase Deficiency
Deficiency Of Acid Maltase
Deficiency Of Alpha-Glucosidase
Deficiency Of Amyloglucosidase
Deficiency Of Exo-1,4-Alpha-Glucosidase
Deficiency Of Gamma-Amylase
Deficiency Of Glucan 1,4-Alpha-Glucosidase
Deficiency Of Glucoamylase
Deficiency Of Glucoinvertase
Deficiency Of Glucosidosucrase
Deficiency Of Maltase
Generalized Glycogenosis
Glycogen Storage Disease Ii
Glycogenosis, Type Ii
Gsd Type Ii
Generalized Glycogenosis
Glycogen Storage Disease Type Ii
Glycogen Storage Disease Type Ii
Classification Hierarchy
MeSH Tree Number breakdown for C0017921
C10
Nervous System Diseases
C10.228
Central Nervous System Diseases
C10.228.140
Brain Diseases
C10.228.140.163
Brain Diseases, Metabolic
C10.228.140.163.100
Brain Diseases, Metabolic, Inborn
C10.228.140.163.100.435
Lysosomal Storage Diseases, Nervous System
C10.228.140.163.100.435.340
Glycogen Storage Disease Type II
C16
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
C16.320
Genetic Diseases, Inborn
C16.320.565
Metabolism, Inborn Errors
C16
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
C16.320
Genetic Diseases, Inborn
C16.320.565
Metabolism, Inborn Errors
C16
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
C16.320
Genetic Diseases, Inborn
C16.320.565
Metabolism, Inborn Errors
C18
Nutritional and Metabolic Diseases
C18.452
Metabolic Diseases
C18.452.132
Brain Diseases, Metabolic
C18
Nutritional and Metabolic Diseases
C18.452
Metabolic Diseases
C18.452.648
Metabolism, Inborn Errors
C18
Nutritional and Metabolic Diseases
C18.452
Metabolic Diseases
C18.452.648
Metabolism, Inborn Errors
C18
Nutritional and Metabolic Diseases
C18.452
Metabolic Diseases
C18.452.648
Metabolism, Inborn Errors
ADE Molecular Mechanism Mapping
Drug-ADE-Human Protein Triplets
Molecular mechanism triplets showing drug-adverse event-protein relationships
0
Total Triplets
0
High Confidence
Loading Drug-ADE-Protein triplets...
Personalized Drug-Protein-ADE Network
Comprehensive Information for Personalized ADE
Comprehensive Information and Reliability for Drug-ADE Association
Drug Confidence Filter
DTA Confidence Level
Layout Style
Show Labels
Total Drugs
11
1 High |
6 Medium |
4 Low Confidence
Total Proteins
1
Target proteins associated with this ADE
Drug-Protein-ADE association
4
0 Known |
0 High |
0 Middle |
4 Low Confidence
Confidence Profile
0%
Known/High/Middle-confidence interactions
This interactive network visualization shows the relationships between the top 50 drugs (ranked by case number) out of 11 total drugs associated with this adverse event, their known and potential off-target proteins, and the associated adverse effect. The connections indicate binding interactions and mechanistic pathways.
Adverse Drug Event (ADE)
Drug
Protein
Drug-Center
Human Protein-Center
confidence level
Drug Confidence Level Distribution
Drug Type Distribution
Loading ADE information...
Pharmacological Target Class Distribution
Top 8 Function Target Sub Classes
Loading target information...
The Introduction of Drug-AE Confidence Score Grade
| Priority Level | Score Range | Description | Evidence Characteristics |
|---|---|---|---|
| High | Score ≥ 6.67High-priority associations requiring immediate attention. | Strong evidence across multiple dimensions with high statistical significance, robust association measures, and substantial case numbers. Warrant priority pharmacovigilance action. | High P-value scores (significant Adjust-P), Strong ROR/PRR values, Substantial case numbers, Complete dimensional coverage, Minimal data filtering needed. |
| Medium | 3.33 ≤ Score < 6.67Medium-priority associations requiring careful evaluation. | Moderate evidence quality with acceptable statistical significance and association strength. May need additional validation or monitoring before definitive action. | Moderate P-value significance, Reasonable ROR/PRR measures, Adequate case numbers, Partial dimensional coverage, Some data quality considerations. |
| Low | Score < 3.33Low-priority associations with limited evidence strength. | May represent weak signals, insufficient data, or associations requiring extensive additional investigation before any regulatory or clinical consideration. | Weak P-value significance, Low association measures, Limited case numbers, Incomplete dimensional data, Significant data filtering applied. |
The Introduction of Drug-AE Severity Score Grade
| Severity Level | Score Range | Description | Typical outcomes |
|---|---|---|---|
| Minimal | 0 ≤ Score ≤ 0.387 Low severity ADRs requiring minimal intervention. | Events that need medical attention to prevent permanent damage but without hospitalization or life-threatening consequences. | Primarily RI (Required Intervention) outcomes, Outpatient management, Preventive measures, Early intervention prevents escalation. |
| Mild | 0.387 < Score ≤ 0.861 Mild severity events requiring hospitalization. | Mix of intervention-required and hospitalization cases with manageable clinical outcomes and good recovery potential. | Mix of RI and HO outcomes, Initial or prolonged hospitalization, Active medical management, Generally favorable prognosis. |
| Moderate | 0.861 < Score ≤ 1.500 Moderate ADRs resulting in permanent disability. | Higher proportion of hospitalization and disability cases requiring intensive medical management and long-term care planning. | Increased HO and DS outcomes, Permanent disability, Extended hospitalization, Rehabilitation required, Long-term functional impairment. |
| Severe | 1.500 < Score ≤ 2.52High severity life-threatening events with significant morbidity. | Notable presence of disability and life-threatening outcomes requiring emergency intervention and intensive care management. | Prominent DS and LT outcomes, Life-threatening events, Emergency intervention required, ICU admission, High risk of permanent consequences. | Critical | 2.524 < Score ≤ 5.000Critical life-threatening or fatal ADRs with maximum clinical impact. | High proportion of life-threatening events and deaths with very strong drug-event associations requiring immediate regulatory action. | Significant LT and DE outcomes, Fatal events, Emergency life-support measures, Immediate drug discontinuation, Regulatory safety alerts. |
The Introduction of Drug-AE-Protein Confidence Score Grade
| Confidence Level | Relationships | Description | Evidence Types |
|---|---|---|---|
| Known/Valid | Direct DTA relationships | The drug-ADE, drug-target, and target-ADE associations are all derived from the same literature source. | Experimental validation, Clinical evidence |
| High | DT + TA + DA | Two of the three associations (drug-ADE, drug-target, and target-ADE) are derived from the same literature source, while the third is validated by other literature. | Multiple corroborating sources |
| Medium | DT + TA + DA | Two of the three associations (drug-ADE, drug-target, and target-ADE) are validated by separate literature sources. | Partial evidence chain |
| Low | TA + DT | Only target-ADE and drug-target associations are validated by literature sources. | Associative evidence only |
Personalized ADE
Route and Formulation-specified Associations
Pharmaceutic Granularity for Route and Formulation specification
Administration Routes (Total: 9 cases across 2 routes)
Dosage Forms (Total: 3 cases across 1 forms)
Drug Route Analysis
Drug Form Analysis
Drug Route Analysis
| Route | Drug Name | Case Number | Confidence Score | Confidence Level | Severity Score | Severity Level | Details | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading data... | |||||||||
Drug Form Analysis
| Form | Drug Name | Case Number | Confidence Score | Confidence Level | Severity Score | Severity Level | Details | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading data... | |||||||||
Disease-stratified Associations
Personalized Granularity for Disease and Indication Stratification
|
Indication Name
|
Drug Name
|
Case Number
|
Confidence Score
|
Confidence Level
|
Severity Score
|
Severity Level
|
Details |
|---|
DEV TOOL
